Adverse Events and Patient Tolerability of Apomorphine SL 2 and 3 mg: A Cross-Study Analysis of Phase II and III Studies

This publication has 17 references indexed in Scilit:

• The pharmacology and clinical pharmacokinetics of apomorphine SL
  BJU International, 2001
• An open-label, uncontrolled dose-optimization study of sublingual apomorphine in erectile dysfunction
  Clinical Therapeutics, 2001
• Characterising the benefit of apomorphine SL (Uprima®) as an optimised treatment for representative populations with erectile dysfunction
  International Journal Of Impotence Research, 2001
• Apomorphine to Uprima®: the development of a practical erectogenic drug: a personal perspective
  International Journal Of Impotence Research, 2001
• Apomorphine SL (Uprima®): a new treatment for the management of erectile dysfunction
  International Journal Of Impotence Research, 2001
• Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction.
  European Urology, 2001
• Apomorphine: an update of clinical trial results
  International Journal Of Impotence Research, 2000
• Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction
  Urology, 2000
• Recovery of erectile function by the oral administration of apomorphine
  Urology, 1995
• III. Researches into the chemical constitution of the opium bases. Part I.—On the action of hydrochloric acid on morphia
  Proceedings of the Royal Society of London, 1869